NuroPro determines how likely a person is to have a disease like Alzheimer’s, Parkinson’s, or Lou Gehrig’s.
Transgenomic signed a letter of intent to acquire exclusive rights for Power3 Medical Products’ neurodegenerative biomarkers. This includes NuroPro®, a proposed diagnostic for Alzheimer’s and Parkinson’s disease. If a final agreement is inked, Transgenomic will offer NuroPro in its CLIA-certified molecular diagnostics laboratory as well as support the tests with development resources.
NuroPro is based on proteomic technology in which a blood serum sample is drawn from a patient and the concentration of selected biomarkers residing in a panel of 59 blood serum protein biomarkers of neurodegenerative disease is monitored. The test then determines if a patient has a neurodegenerative disease such as Alzheimer’s, Parkinson’s, or Lou Gehrig’s.
The technology assigns a probability score that reflects how closely a patient’s sample fits a biostatistical model for a neurological disease. It thus indicates if the patient should be recommended for a follow-up by the clinician. These technologies would join Transgenomic’s portfolio of molecular diagnostics, which includes tests for mitochondrial disorders, oncology and hematology, molecular pathology, and inherited diseases.
“The proteomic tests for detection of early disease developed by Power3 are very attractive, particularly when combined with our company’s demonstrated strength in robust and sensitive genomics tests for detection of increased disease susceptibility,” notes Craig Tuttle, CEO of Transgenomic. “Moreover, as we are already calling on neurologists with our current lab sales organization, these new assays will add significant depth to our neurological sales portfolio.”
